JellyFil Ingredients: All Nine Extracts On The Printed Panel

First on the panel, and the least studied in people. Muira puama is an Amazonian shrub whose root and bark have been sold as a tonic for well over a century, and it is printed first on this blend, which normally signals the largest share by weight. The published record behind it is almost entirely animal work: a memory experiment in mice found aged mice retrieving a learned task better after oral doses, and a 2003 enzyme study of the root identified activity against the enzyme that clears acetylcholine. Both are laboratory findings in rodents. No randomised human trial of muira puama at any amount appears in the PubMed record, so the honest position is that the first name on this label is the one with the least human evidence behind it.

Sources: a memory experiment in mice · a 2003 enzyme study of the root

The one member with repeated randomised trials. Maca is a Peruvian root vegetable, and it is the only botanical here with more than one randomised trial to its name. In the 2002 randomised maca trial, twelve weeks of 1,500 mg or 3,000 mg a day raised self-reported sexual desire in healthy men while leaving serum testosterone unchanged, which is a useful pair of results to hold together. A later a systematic review of maca trials of the trial record called the evidence suggestive rather than settled and asked for larger studies. A separate a dose-finding trial of maca root trial used 1.5 g and 3 g a day. Every one of those amounts is measured in grams; the whole blend here is 82 mg.

Sources: the 2002 randomised maca trial · a systematic review of maca trials · a dose-finding trial of maca root · MedlinePlus on maca

The name covers more than one plant. Catuaba is the most interesting name on this panel for a reason that has nothing to do with what it does. When Austrian pharmacognosists ran an analysis of commercial catuaba through morphological and chemical analysis, they found that material sold under the name came from different botanical sources with different constituents, so two bottles labelled catuaba need not contain the same plant. The label here prints Catuaba Extract and no species, which is normal for the trade and is worth knowing before comparing this panel with any other.

Sources: an analysis of commercial catuaba

A well-studied catechin extract. Green tea extract is printed fourth on the panel and appears nowhere in the seller's six-name graphic. It is a real omission rather than a trivial one: the catechin fraction of green tea is among the better-studied plant extracts in circulation, with a meta-analysis of green tea and blood pressure pooling randomised trials at a median near 400 mg of catechins a day, and the the US Pharmacopeia review of green tea extract review of case reports is the reason several regulators now ask for a warning on concentrated extracts. At the share of 82 mg that nine names can leave it, the amount here sits far below both the studied and the cautioned range.

Absent from the seller’s own ingredient graphic, which is headed with six names. This one is printed on the panel of the bottle that arrives.

Sources: a meta-analysis of green tea and blood pressure · the US Pharmacopeia review of green tea extract · NCCIH on green tea

The only member of the blend with its own figure. Caffeine sits inside the blend with a number beside it, which makes it the one ingredient on this bottle a buyer can compare with anything else. Five milligrams is very small: a cup of brewed coffee runs 80 mg to 100 mg, and the the FDA consumer update on caffeine sets 400 mg a day as the figure most healthy adults tolerate. An an umbrella review of caffeine research of the research found most outcomes neutral or favourable in that range, while a meta-analysis in adults with high blood pressure reported measurable blood-pressure effects in people already treated for hypertension. Five milligrams a day is unlikely to be felt by anyone, and it still belongs on a label a buyer reads before bed.

Absent from the seller’s own ingredient graphic, which is headed with six names. This one is printed on the panel of the bottle that arrives.

Sources: the FDA consumer update on caffeine · an umbrella review of caffeine research · a meta-analysis in adults with high blood pressure

Strong trial record, at amounts this blend cannot reach. Ashwagandha has the largest randomised literature of anything on this panel. A a meta-analysis of stress and anxiety trials meta-analysis of trials using 240 mg to 600 mg a day of root extract found measurable reductions in stress and anxiety scores; a 2026 a 2026 meta-analysis of hormone outcomes meta-analysis looked specifically at hormonal outcomes; and a meta-analysis in male fertility pooled the male-fertility trials, several of which used 5 g a day of root powder. It also carries the clearest safety signal here: a case series from two national registries describes reported liver injury from two national registries, which is why the NCCIH on ashwagandha page on it exists.

Sources: a meta-analysis of stress and anxiety trials · a 2026 meta-analysis of hormone outcomes · a meta-analysis in male fertility · a case series from two national registries · NCCIH on ashwagandha

The one amino acid on the panel. Arginine is the amino acid the body uses to make nitric oxide, which relaxes the smooth muscle in blood-vessel walls. That is a real and well-mapped pathway, and it is also where the arithmetic on this label is at its starkest. a pharmacokinetic comparison of the two amino acids gave healthy adults single oral doses of 3 g and 6 g and tracked what reached the bloodstream; the a review of oral arginine and blood pressure review of blood-pressure work discusses amounts in the same range. Those are grams. Nine names share 82 milligrams here, so arginine's share is a fraction of a percent of what the trials measured.

Sources: a pharmacokinetic comparison of the two amino acids · a review of oral arginine and blood pressure

The one the trial record has answered. Tribulus is sold across this whole category on the strength of a hormonal story, and it is the member of this panel where the published answer is least ambiguous. A 2026 a 2026 meta-analysis of tribulus trials meta-analysis of randomised trials, at roughly 750 mg to 1,500 mg a day, found the effect on erectile-function scores small and inconsistent and no reliable change in testosterone. The broader an evidence review of this whole product category review of this product category reached the same conclusion about it. It is on the bottle, it is named in the advertising, and it is the one to expect least from.

Sources: a 2026 meta-analysis of tribulus trials · an evidence review of this whole product category

The omission with the most to say about safety. Horny goat weed is the ninth name on the panel and the third the advertising leaves out, and of the three it is the one a buyer most needs to see. Its marker compound, icariin, is a weak inhibitor of the same enzyme that prescription erectile-dysfunction tablets block: the 2010 laboratory study of icariin demonstrated the effect in cell culture and in rats, and a review of plant PDE-5 inhibitors places it among the plant constituents with measurable activity at that target. That shared mechanism is exactly why MedlinePlus on epimedium lists interactions with nitrates and with blood-pressure medicines, and it is the sentence that should have been in the advertising.

Absent from the seller’s own ingredient graphic, which is headed with six names. This one is printed on the panel of the bottle that arrives.

Sources: the 2010 laboratory study of icariin · a review of plant PDE-5 inhibitors · MedlinePlus on epimedium